TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27932051

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET) at 1 month and 12 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) assessment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dyspnea assessment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 6-min walk distance (6MWD) testing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Residual clot burden measurement (perfusion scan, CT pulmonary angiography)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cardiac function assessment (echocardiography)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (PFTs)
Number of subjects: 100
Study: 27932068

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine 0.2 mg/kg every 3 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine 0.4 mg/kg every 3 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine 0.3 mg/kg every 6 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine 0.4 mg/kg every 6 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine 0.8 mg/kg every 3 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (various doses)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (high DLL3 expression)
Number of subjects: 82
Study: 27932427

Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker (implanted for <6 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker (implanted for ≥ 6 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker (chronic retrieval cohort)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Leadless cardiac pacemaker retrieval procedure
Number of subjects: 16
Study: 27932562

Group type: EXPERIMENTAL
Intervention: Cerenkov luminescence imaging (CLI) for intraoperative assessment of tumor resection margins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard methods for assessing resection margins (not specified)
Number of subjects: 0
Study: 27932629

Group type: EXPERIMENTAL
Intervention: London Chest Activities of Daily Living Scale
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Chronic Respiratory Questionnaire
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Palliative care Outcome Scale
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Palliative care Outcome Scale-symptoms
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Breathlessness measured on a numerical rating scale
Number of subjects: 88
Study: 27932687

Group type: EXPERIMENTAL
Intervention: High diabetes distress
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: High diabetes distress (<18 years)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Low or moderate diabetes distress
Number of subjects: 268
Study: 27933186

Group type: EXPERIMENTAL
Intervention: High GI (GI≥65) with high carbohydrate (58% kcal)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Low GI (GI≤45) with low carbohydrate (40% kcal)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Low GI with high carbohydrate
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: High GI with low carbohydrate
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Reducing carbohydrate content (regardless of GI)
Number of subjects: 163
Study: 27933199

Group type: EXPERIMENTAL
Intervention: RCI 40 U daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: RCI 80 U every other day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Combined placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: RCI treatment
Number of subjects: 38
Study: 27933201

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Definite NASH
Number of subjects: 356

Group type: COMPARATOR
Intervention: No MetS
Number of subjects: 356
Study: 27933289

Group type: EXPERIMENTAL
Intervention: Higher age at immigration and increased duration of stay in the US
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Family reunification
Number of subjects: 238

Group type: COMPARATOR
Intervention: Unhealthy assimilation behavior (higher prevalence of smoking, alcohol consumption, or sedentary activity)
Number of subjects: 238
Study: 27933679

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation for 2 weeks
Number of subjects: 60
Study: 27935524

Group type: EXPERIMENTAL
Intervention: Low urinary potassium excretion (UKV <55 mmol/24 h for women; <65 mmol/24 h for men)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Mean urinary potassium excretion (UKV) in RTRs
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Follow-up duration
Number of subjects: 705
Study: 27935737

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) for 30 minutes, three times weekly for 4 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 53
Study: 27935867

Group type: EXPERIMENTAL
Intervention: OTX015 (MK-8628)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Combination of OTX015 and everolimus
Number of subjects: 3

Group type: COMPARATOR
Intervention: Everolimus alone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: OTX015 as single agent
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Combination with everolimus
Number of subjects: 3
Study: 27936016

Group type: EXPERIMENTAL
Intervention: Wild-Type HRV-16 Challenge Virus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inoculation with 1 TCID50
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inoculation with 10 TCID50
Number of subjects: 0
Study: 27938399

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: WC
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: WHtR
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Central obesity
Number of subjects: 738
Study: 27938896

Group type: EXPERIMENTAL
Intervention: Home administration of intranasal LAIV by parents
Number of subjects: 41
Study: 27938897

Group type: COMPARATOR
Intervention: Naloxegol
Number of subjects: 1337
Study: 27938911

Group type: EXPERIMENTAL
Intervention: Propofol (3 mg/kg) infusion for 10 minutes
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no sedation)
Number of subjects: 48
Study: 27939059

Group type: EXPERIMENTAL
Intervention: Nusinersen 12 mg dose
Number of subjects: 20
Study: 27939380

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27939400

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg intravenous every 21 days until progression
Number of subjects: 123
Study: 27940595

Group type: EXPERIMENTAL
Intervention: Giant cell arteritis patients with prevalent stroke
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Giant cell arteritis patients with peripheral vascular disease
Number of subjects: 433
Study: 27940636

Group type: EXPERIMENTAL
Intervention: High-resolution ultrasonography of peripheral and spinal nerves
Number of subjects: 205
Study: 27940685

Group type: EXPERIMENTAL
Intervention: Prenatal maternal iron deficiency (ID)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Prenatal ID anemia (IDA) at delivery
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Iron supplementation during pregnancy
Number of subjects: 636
Study: 27940696

Group type: EXPERIMENTAL
Intervention: NIAAA SG
Number of subjects: 1573

Group type: EXPERIMENTAL
Intervention: CRAFFT
Number of subjects: 1573

Group type: EXPERIMENTAL
Intervention: PESQ-PS
Number of subjects: 1573

Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test
Number of subjects: 1573

Group type: EXPERIMENTAL
Intervention: PESQ-PS and CRAFFT
Number of subjects: 1573
Study: 27941019

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1388
Study: 27941066

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration during PCI
Number of subjects: 180306

Group type: COMPARATOR
Intervention: PCI alone
Number of subjects: 180306

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration during PCI (high thrombus burden)
Number of subjects: 180306

Group type: COMPARATOR
Intervention: PCI alone (high thrombus burden)
Number of subjects: 180306
Study: 27941217

Group type: EXPERIMENTAL
Intervention: Automated RR-interval series calculated with the AIT Multi-Lead ECGsolver
Number of subjects: 339

Group type: COMPARATOR
Intervention: Manually reviewed reference RR-time series
Number of subjects: 339
Study: 27942587

Group type: EXPERIMENTAL
Intervention: Chorioretinal thinning assessment in chronic kidney disease patients
Number of subjects: 0
Study: 27942917

Group type: EXPERIMENTAL
Intervention: LJM716 (40 mg/kg, intravenously, once weekly in 28-day cycles)
Number of subjects: 12
Study: 27943107

Group type: EXPERIMENTAL
Intervention: IDegLira once daily
Number of subjects: 438

Group type: COMPARATOR
Intervention: Unchanged GLP-1RA therapy
Number of subjects: 438
Study: 27955679

Group type: EXPERIMENTAL
Intervention: Flutemetamol F 18 injection
Number of subjects: 0
Study: 27955681

Group type: EXPERIMENTAL
Intervention: Biodegradable polymeric sealant
Number of subjects: 112
Study: 27955684

Group type: EXPERIMENTAL
Intervention: Pertuzumab (840 mg loading, 420 mg maintenance doses) and Trastuzumab (8 mg/kg loading, 6 mg/kg maintenance doses), followed by Vinorelbine (25 mg/m2)
Number of subjects: 106
Study: 27955875

Group type: EXPERIMENTAL
Intervention: Ongoing child and family education and self-management support
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Environmental control and housing resources
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Linkages to smoking cessation programs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Psychosocial support
Number of subjects: 13
Study: 27956157

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once daily until progression or unacceptable toxicity
Number of subjects: 31
Study: 27956377

Group type: EXPERIMENTAL
Intervention: Standard care plus guaranteed incentives (Can $1 per day step goal met)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (wellness program, accelerometer)
Number of subjects: 100
Study: 27956421

Group type: EXPERIMENTAL
Intervention: Miltefosine (Impavido) at a nominal dose of 2.5 mg/kg/day for 28 days
Number of subjects: 60
Study: 27956671

Group type: EXPERIMENTAL
Intervention: Urine flow rate during CPB
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Urine flow rate <1.5 ml/kg
Number of subjects: 503
Study: 27957340

Group type: EXPERIMENTAL
Intervention: Conventional Flexible Bronchoscopy with Multiplanar CT Planning
Number of subjects: 0
Study: 27958229

Group type: EXPERIMENTAL
Intervention: Incidence of sepsis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etiology of sepsis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Independent risk factors for increased mortality from sepsis
Number of subjects: 0
Study: 27959685

Group type: EXPERIMENTAL
Intervention: Screened donations (n=75,331)
Number of subjects: 89153

Group type: COMPARATOR
Intervention: Unscreened donations (n=253,031)
Number of subjects: 89153
Study: 27959707

Group type: EXPERIMENTAL
Intervention: Severe acute kidney injury (stage 2 or 3)
Number of subjects: 4683

Group type: COMPARATOR
Intervention: No severe acute kidney injury
Number of subjects: 4683

Group type: EXPERIMENTAL
Intervention: Severe acute kidney injury
Number of subjects: 4683

Group type: EXPERIMENTAL
Intervention: Acute kidney injury severity
Number of subjects: 4683
Study: 27959728

Group type: EXPERIMENTAL
Intervention: VRC01 (bNAb targeting HIV CD4-binding site)
Number of subjects: 24
Study: 27959731

Group type: EXPERIMENTAL
Intervention: Decitabine (20 mg/m²/day for 10 consecutive days in monthly cycles)
Number of subjects: 116
Study: 27959736

Group type: EXPERIMENTAL
Intervention: Fully implanted brain-computer interface with subdural electrodes over the motor cortex and a subcutaneously placed transmitter.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Brain-computer interface
Number of subjects: 1
Study: 27964737

Group type: EXPERIMENTAL
Intervention: Diagnostic Decision Support Software (DDSS)
Number of subjects: 26
Study: 27964867

Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy (anti-CD22)
Number of subjects: 71
Study: 27964869

Group type: EXPERIMENTAL
Intervention: Voluntary methadone treatment in VTCs
Number of subjects: 184

Group type: COMPARATOR
Intervention: Compulsory drug detention centres (CDDCs)
Number of subjects: 184
Study: 27965253

Group type: EXPERIMENTAL
Intervention: Web-based Guided Self-Determination (GSD) intervention
Number of subjects: 0
Study: 27965258

Group type: EXPERIMENTAL
Intervention: Immunoassays performed with blood samples from patients
Number of subjects: 3
Study: 27965782

Group type: EXPERIMENTAL
Intervention: Facilitated intervention based on the PARiHS framework
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 10
Study: 27965789

Group type: EXPERIMENTAL
Intervention: 20 ml 0.5% ropivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 ml 0.33% ropivacaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 40 ml 0.25% ropivacaine
Number of subjects: 30
Study: 27965798

Group type: EXPERIMENTAL
Intervention: Probiotics administered to mechanically ventilated critically ill patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27965808

Group type: EXPERIMENTAL
Intervention: Multi-component physiotherapist-led intervention including a 40-min education module, guided goal-setting, action planning, wristband activity tracker, and weekly follow-up phone calls.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Delayed-intervention group (5-week delay before intervention).
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Immediate-intervention group (4-week intervention).
Number of subjects: 36

Group type: COMPARATOR
Intervention: N/A (baseline measures).
Number of subjects: 36
Study: 27965809

Group type: EXPERIMENTAL
Intervention: Glycerin suppository (250 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (250 mg glycerin suppository placed in the diaper)
Number of subjects: 30
Study: 27965816

Group type: EXPERIMENTAL
Intervention: Diagnostic pathways (16 possible combinations of diagnostic tools)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Data collection on clinical history, diagnostic path, treatment, and urine culture
Number of subjects: 200
Study: 27965817

Group type: EXPERIMENTAL
Intervention: Behavioural activation (BA) added to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Depression support group with usual care
Number of subjects: 0
Study: 27965841

Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA) group therapy
Number of subjects: 0
Study: 27965843

Group type: EXPERIMENTAL
Intervention: Aging, Community and Health-Community Partnership Program (6-month interprofessional, nurse-led program)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Aging, Community and Health-Community Partnership Program
Number of subjects: 51
Study: 27965842

Group type: EXPERIMENTAL
Intervention: HN-STAR (Head and Neck Survivorship Tool: Assessment and Recommendations), an electronic platform for personalized care in cancer survivorship clinics.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HN-STAR
Number of subjects: 0
Study: 27965845

Group type: EXPERIMENTAL
Intervention: General health education condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Healthy eating physical activity skills condition
Number of subjects: 40
Study: 27965856

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study: 27965861

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET) program, 12-week duration, supervised, progressive intensity, 2 sessions per week, 45 minutes each.
Number of subjects: 0
Study: 27965866

Group type: EXPERIMENTAL
Intervention: Natural progesterone (Prometrium, 200 mg) vaginally every night from gestational week 16 to 36
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 40
Study: 27965873

Group type: EXPERIMENTAL
Intervention: My MFG (mobile health application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27965885

Group type: EXPERIMENTAL
Intervention: Music therapy (two 30-45 min sessions per week for three consecutive weeks, in addition to care as usual)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 52
Study: 27966809

Group type: EXPERIMENTAL
Intervention: Carboxypeptidase G2 (CPDG) administered to 47 children
Number of subjects: 1286

Group type: COMPARATOR
Intervention: High-dose methotrexate (5 g/m2)
Number of subjects: 1286
Study: 27967215

Group type: EXPERIMENTAL
Intervention: Intramuscular triamcinolone acetonide (TA)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 526
Study: 27973930

Group type: EXPERIMENTAL
Intervention: Mechanical ventilator support (invasive or noninvasive)
Number of subjects: 78
Study: 27974047

Group type: EXPERIMENTAL
Intervention: TRK inhibition
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: FGFR1 gene fusions (FGFR1-HOOK3, FGFR1-TACC1)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Comprehensive genomic profiling (CGP)
Number of subjects: 186
Study: 27974310

Group type: EXPERIMENTAL
Intervention: Serum potassium (high-normal)
Number of subjects: 2157

Group type: COMPARATOR
Intervention: Serum potassium (low-normal)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Aldosterone (normal <9 ng/dL)
Number of subjects: 2157

Group type: EXPERIMENTAL
Intervention: Aldosterone (high-normal ≥9 ng/dL)
Number of subjects: 2157

Group type: COMPARATOR
Intervention: Dietary potassium
Number of subjects: 2157

Group type: COMPARATOR
Intervention: Urinary potassium
Number of subjects: 2157
Study: 27974370

Group type: EXPERIMENTAL
Intervention: CT scanning for all anticoagulated patients with head injury
Number of subjects: 3566

Group type: COMPARATOR
Intervention: Selective CT use based on guidelines
Number of subjects: 3566
Study: 27974525

Group type: EXPERIMENTAL
Intervention: 16S rRNA gene PCR for rapid exclusion of VAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microbiological cultures
Number of subjects: 0
Study: 27974691

Group type: EXPERIMENTAL
Intervention: US-guided Nd:YAG laser ablation
Number of subjects: 4

Group type: COMPARATOR
Intervention: Literature review of thermal ablation
Number of subjects: 4
Study: 27974888

Group type: EXPERIMENTAL
Intervention: Telekit System from the Danish TeleCare North Trial
Number of subjects: 0
Study: 27977002

Group type: EXPERIMENTAL
Intervention: Home telemonitoring
Number of subjects: 900
Study: 27977390

Group type: EXPERIMENTAL
Intervention: WAPPS-Hemo Web-based calculator for individualized pharmacokinetic estimation
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetics models
Number of subjects: 878
Study: 27977934

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 5598

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 5598

Group type: COMPARATOR
Intervention: Non-canagliflozin treatments (placebo, sitagliptin, glimepiride)
Number of subjects: 5598

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 5598
Study: 27978559

Group type: EXPERIMENTAL
Intervention: OCT-Leakage algorithm
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group of 25 healthy eyes
Number of subjects: 48
Study: 27978569

Group type: EXPERIMENTAL
Intervention: Low-vision devices with therapy
Number of subjects: 323

Group type: COMPARATOR
Intervention: Low-vision devices without therapy
Number of subjects: 323
Study: 27978840

Group type: EXPERIMENTAL
Intervention: Phenotype 1: mild, good lung function, early onset, low-inflammatory, predominantly Type-2
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Phenotype 2: moderate, hyper-responsive, eosinophilic, moderate asthma control, mild airflow obstruction, predominant Type-2 inflammation
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Phenotype 3: mixed severity, predominantly fixed obstructive, non-eosinophilic and neutrophilic, moderate asthma control, low Type-2 inflammation
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Phenotype 4: severe uncontrolled, severe reversible obstruction, mixed granulocytic, moderate Type-2 inflammation
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Cluster classification probabilities derived from ADEPT data
Number of subjects: 156
Study: 27979025

Group type: EXPERIMENTAL
Intervention: Atopy patch tests (APTs) with locally lyophilized food allergens
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) with locally lyophilized food allergens
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Atopy patch tests (APTs) for D. farinae, D. pteronyssinus, and American cockroach
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) for D. farinae, D. pteronyssinus, and American cockroach
Number of subjects: 56
Study: 27979791

Group type: EXPERIMENTAL
Intervention: Barriers to Diabetes Adherence in adolescent scale
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Self-Efficacy for Diabetes Self-Management measure
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: World Health Organization-5 Well-Being Index
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Closed-ended questions and open-ended questions
Number of subjects: 380
Study: 27980409

Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/d
Number of subjects: 2218

Group type: EXPERIMENTAL
Intervention: Vilazodone 20-40 mg/d
Number of subjects: 2218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2218
Study: 27980462

Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg QD
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Enoxaparin 20 mg BID
Number of subjects: 1326
Study: 27980605

Group type: EXPERIMENTAL
Intervention: Early neonatal food (ENF) feeding
Number of subjects: 25286

Group type: COMPARATOR
Intervention: Control (no ENF feeding)
Number of subjects: 25286
Study: 27980771

Group type: EXPERIMENTAL
Intervention: Neurobiologically based five-day treatment for anorexia nervosa
Number of subjects: 37